IASO Biotherapeutics

About IASO Biotherapeutics

IASO Bio focuses on innovative biotherapies to bring hope of cure to patients, aspiring to provide new and curative treatments in the fields of hematologic malignancies and autoimmune diseases. The company integrates capabilities across discovery, development, manufacturing, and commercialization.

Products & Services

Pipeline:Diversified and balanced pipeline developed with a forward-looking, de-risked development approach.

Technology Platform:Leading and integrated platforms leveraging advanced technologies spanning the entire product lifecycle.

Manufacturing:A mature and stable CMC platform enabling large-scale, high-quality manufacturing.

Equecabtagene Autoleucel (Fucaso):A CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.

Specialties

CAR-T Therapy Cell Therapy Hematologic Malignancies Autoimmune Diseases Dual-Targeted CAR-T

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C1 T: - FT: Series C1	A: 75000000 MR: - FA: nearly US $75 million FAN: 75000000	D: 2023-01-17 FD: 2023-01-17	6 investors

Series C1 Latest

2023-01-17

$75.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Chen Dong

Director and Professor, Institute for Immunology, Tsinghua University

L

Lugui Qiu

Chief Clinical Expert, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

N

Nikhil C. Munshi

Kraft Family Chair and Professor of Medicine at Harvard Medical School

J

Jinhua Zhang

Founder, Chairwoman, and CEO

Y

Yongke Zhang, M.D., Ph.D.

Chief Scientific Officer and Senior Vice President

H

Hua Zhang

Chief Commercial Officer and Senior Vice President

View 7 more team members with Pro

Unlock Full Team Directory

Recent News